Novavax (NVAX) Received its Third Buy in a Row
After Ladenburg Thalmann & Co. and Cantor Fitzgerald gave Novavax (NASDAQ: NVAX) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Kevin DeGeeter maintained a Buy rating on Novavax today and set a price target of $19.00. The company’s shares closed last Tuesday at $14.90.
According to TipRanks.com, DeGeeter is a 3-star analyst with an average return of 1.5% and a 36.6% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Molecular Templates, and Cidara Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Novavax with a $22.00 average price target, representing a 36.6% upside. In a report issued on March 24, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $24.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.71 and a one-year low of $3.54. Currently, Novavax has an average volume of 8.43M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Read More on NVAX: